The AnteoTech (ASX:ADO) share price RAT-tles down 8% following TGA update

The TGA has asked for more clinical data, so further trials will now be conducted.

| More on:
A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • The AnteoTech share price is dropping today
  • The healthcare company is seeking TGA approval for its rapid antigen tests (RATs) 
  • New clinical trials will be conducted to meet TGA requirements

The Anteotech Ltd (ASX: ADO) share price is falling today after the healthcare company announced it has another hoop to jump through regarding its COVID-19 rapid antigen tests (RATs).

At the time of writing, the AnteoTech share price is down 8.5% to 22 cents.

Let's take a look at what's happening…

New requirement for AnteoTech RAT tests

AnteoTech is seeking approval from the Therapeutic Goods Administration (TGA) to register its RAT test for COVID-19.

The RAT incorporates AnteoTech's existing EuGeni Reader technology with a SARS CoV-2 Ag Rapid Diagnostic Test (RDT).

If successful, the approval would allow AnteoTech to market and commercialise its RAT for Australian use. There is also the potential for expansion into larger markets.

The company prides its EuGeni Reader as being a "fast, accurate and compact solution for rapid point-of-care testing". It has been adapted to create the RAT and results so far indicate "a 97.3% sensitivity" rate.

However, AnteoTech has not yet been successful.

The healthcare company made the initial submission back in September. Today marks the third registration update released to shareholders. In it, the TGA asks for more clinical data from COVID-19 patients using the device.

In order to proceed with the application, further clinical trials will be conducted in Europe and Australia. Once the required data is obtained, AnteoTech intends to compile a new submission to the TGA.

Comment from management

AnteoTech said these new trials will demonstrate the product's performance "relating to new variants of concern listed by the World Health Organisation (WHO), lower limit of detection and other performance measures from a vaccinated population".

AnteoTech CEO Derek Thomson said:

We have worked directly with the TGA to understand the most efficient method of supplying the data they now require and our highest priority is to generate this data as quickly as possible.

These further trials will provide AnteoTech with the opportunity to gain additional clinical data which will enhance the growing body of evidence for performance of both the EuGeni Reader and the RDT.

AnteoTech share price snapshot

The AnteoTech share price started to pick up in the middle of 2020, right in the midst of the pandemic. Beforehand, its shares were trading around 1 cent each.

Shares reached a new high in April last year, hitting 44 cents each.

The AnteoTech share price has been fluctuating in 2022. The highlight has been a 30% gain in the first week of February.

The healthcare company has a market capitalisation of $426 million and 1.97 billion shares on issue.

Motley Fool contributor Alice de Bruin has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Why CSL shares could be a bargain buy at $240

Let's see what Bell Potter is saying about this blue chip.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »